^
Association details:
Biomarker:EGFR L861Q
Cancer:Esophageal Cancer
Drug:erlotinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Excerpt:
...in the present study, the KYSE270 cell line with an EGFR L861Q mutation was hypersensitive to afatinib….This cell line, however, was not sensitive to erlotinib, a reversible EGFR inhibitor.
DOI:
10.1158/1535-7163.MCT-15-0737